Vorapaxar expands antiplatelet options which patients may benefit from thrombin receptor antagonism?

Hamostaseologie

Volumn 32, Issue 3, 2012, Pages 221-227

  Duerschmied, Daniel ^a   Bode, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antiplatelet therapy; Atherothrombosis; Vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; ATOPAXAR; CLOPIDOGREL; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; RIVAROXABAN; THROMBIN RECEPTOR ANTAGONIST; VORAPAXAR;

ANTICOAGULANT THERAPY; CARDIOVASCULAR MORTALITY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; INTRACELLULAR SIGNALING; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; REVIEW; THROMBOLYSIS IN MYOCARDIAL INFARCTION;

EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; LACTONES; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTORS, THROMBIN; THROMBOSIS; TREATMENT OUTCOME;

EID: 84867619644     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-12-05-0006     Document Type: Review

References (41)

1. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
2. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32: 2999-3054.
3. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Circulation 2011; 124: e574-e651.
4. Anderson JL, Adams CD, Antman EM et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Circulation. 2011; 123: e426-e579.
5. Guagliumi G, Sirbu V, Musumeci G et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv 2012; 5: 12-20.
6. Tricoci P, Huang Z, Held C et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33.
7. Morrow DA, Braunwald E, Bonaca MP et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413.
8. Silvain J, Collet JP, Nagaswami C et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57: 1359-1367.
9. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 728-739.
10. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-297.
11. Duerschmied D, Bode C, Moser M. Clopidogrel in acute coronary syndrome: implications of recent study findings. Expert Rev Cardiovasc Ther 2010; 8: 1215-1229.
12. Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 2010; 121: 569-583.
13. Ahrens I, Bode C. Novel antiplatelet therapies following percutaneous coronary interventions. Curr Opin Investig Drugs 2009; 10: 902-911.
14. Reininger AJ, Bernlochner I, Penz SM et al. A 2-Step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 2010; 55: 1147-1158.
15. Bergmeier W, Piffath CL, Goerge T et al. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci USA 2006; 103: 16900-16905.
16. Nieswandt B, Brakebusch C, Bergmeier W et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. Embo J 2001; 20: 2120-2130.
17. Nesbitt WS, Westein E, Tovar-Lopez FJ et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009; 15: 665-673.
18. Ruggeri ZM, Orje JN, Habermann R et al. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 2006; 108: 1903-1910.
19. Stefanini L, Roden RC, Bergmeier W. CalDAGGEFI is at the nexus of calcium-dependent platelet activation. Blood 2009; 114: 2506-2514.
20. Cifuni SM, Wagner DD, Bergmeier W. CalDAGGEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets. Blood 2008; 112: 1696-1703.
21. Crittenden JR, Bergmeier W, Zhang Y et al. Cal-DAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004; 10: 982-986.
22. Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM et al. Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest. 2005; 115: 680-687.
23. Stefanini L, Boulaftali Y, Ouellette TD et al. Rap1-rac1 circuits potentiate platelet activation. Arterioscler Thromb Vasc Biol 2012; 32: 434-441.
24. Stolla M, Stefanini L, Roden RC et al. The kinetics of alphaIIbbeta3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy. Blood 2011; 117: 1005-1013.
25. Coughlin SR. Thrombin signalling and proteaseactivated receptors. Nature 2000; 407: 258-264.
26. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068.
27. Sambrano GR, Weiss EJ, Zheng YW et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-78.
28. Andersen H, Greenberg DL, Fujikawa K et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999; 96: 11189-11193.
29. Hildemann SK, Bode C. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1. Hämostaseologie 2009; 29: 349-355.
30. Chintala M, Strony J, Yang B et al. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 2010; 30: 2143-2149.
31. Becker RC, Moliterno DJ, Jennings LK et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-928.
32. Goto S, Yamaguchi T, Ikeda Y et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 2010; 17: 156-164.
33. Shah R. Protease-activated receptors in cardiovascular health and diseases. Am Heart J 2009; 157: 253-262.
34. Kahn ML, Zheng YW, Huang W et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-694.
35. Kogushi M, Matsuoka T, Kuramochi H et al. Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats. Eur J Pharmacol 2011; 666: 158-164.
36. Wiviott SD, Flather MD, O'Donoghue ML et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation 2011; 123: 1854-1863.
37. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J 2009; 158: 327-334 e4.
38. Morrow DA, Scirica BM, Fox KA et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009; 158: 335-341 e3.
39. oP): TIMI 50 Trial. American College of Cardiology's (ACC's) 61st Annual Scientific Session. 2012 March 24.
40. Tricoci P, Newby LK, Hasselblad V et al. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Circ Cardiovasc Qual Outcomes 2011; 4: 448-458.
41. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.